DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hypereosinophilic Syndrome - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Hypereosinophilic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypereosinophilic Syndrome and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Hypereosinophilic Syndrome Overview
- Therapeutics Development
- Pipeline Products for Hypereosinophilic Syndrome - Overview
- Pipeline Products for Hypereosinophilic Syndrome - Comparative Analysis
- Hypereosinophilic Syndrome - Therapeutics under Development by Companies
- Hypereosinophilic Syndrome - Therapeutics under Investigation by Universities/Institutes
- Hypereosinophilic Syndrome Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Hypereosinophilic Syndrome - Products under Development by Companies
- Hypereosinophilic Syndrome - Products under Investigation by Universities/Institutes
- Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Knopp Biosciences LLC
- Kyowa Hakko Kirin Co., Ltd.
- Stemline Therapeutics, Inc.
For more information visit http://www.researchandmarkets.com/research/76cvtd/hypereosinophilic
